Literature DB >> 1672256

The long term prognostic significance of c-erbB-2 in primary breast cancer.

J Winstanley1, T Cooke, G D Murray, A Platt-Higgins, W D George, S Holt, M Myskov, A Spedding, B R Barraclough, P S Rudland.   

Abstract

The expression of the c-erbB-2 oncogene has been evaluated using an immunohistochemical technique with the 21N polyclonal antibody in paraffin embedded tissue from 465 patients treated between the years 1975-1981 for Stage I and II breast cancer. One hundred and four (22%) patients exhibited positive staining. This was not associated with any other variables. Expression of the oncogene was associated with significantly poorer survival which was independent of other tumour variables.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1672256      PMCID： PMC1971845          DOI： 10.1038/bjc.1991.103

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  20 in total

1.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.

Authors:  J M Varley; J E Swallow; W J Brammar; J L Whittaker; R A Walker
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

2.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

Authors:  C I Bargmann; M C Hung; R A Weinberg
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.

Authors:  N R Lemoine; S Staddon; C Dickson; D M Barnes; W J Gullick
Journal:  Oncogene       Date:  1990-02       Impact factor: 9.867

4.  Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas.

Authors:  L C Padhy; C Shih; D Cowing; R Finkelstein; R A Weinberg
Journal:  Cell       Date:  1982-04       Impact factor: 41.582

5.  Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.

Authors:  D J Venter; N L Tuzi; S Kumar; W J Gullick
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

6.  Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.

Authors:  D Zhou; H Battifora; J Yokota; T Yamamoto; M J Cline
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

7.  Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene.

Authors:  M van de Vijver; R van de Bersselaar; P Devilee; C Cornelisse; J Peterse; R Nusse
Journal:  Mol Cell Biol       Date:  1987-05       Impact factor: 4.272

8.  Oestrogen receptors and prognosis in early breast cancer.

Authors:  T Cooke; D George; R Shields; P Maynard; K Griffiths
Journal:  Lancet       Date:  1979-05-12       Impact factor: 79.321

9.  Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma.

Authors:  I U Ali; G Campbell; R Lidereau; R Callahan
Journal:  Oncogene Res       Date:  1988-09

10.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.

Authors:  D M Barnes; G A Lammie; R R Millis; W L Gullick; D S Allen; D G Altman
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640
View more
  48 in total

1.  Flow Cytometric Assay of c-erbB-2 Protein in Fine Needle Aspirates of Fresh and Frozen Human Breast Cancer Tissues.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

2.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

3.  Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.

Authors:  S W Beenken; W E Grizzle; D R Crowe; M G Conner; H L Weiss; M T Sellers; H Krontiras; M M Urist; K I Bland
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

Review 4.  Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.

Authors:  Attiqa N Mirza; Nadeem Q Mirza; Georges Vlastos; S Eva Singletary
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

5.  Personalized medicine in breast cancer: a systematic review.

Authors:  Sang-Hoon Cho; Jongsu Jeon; Seung Il Kim
Journal:  J Breast Cancer       Date:  2012-09-28       Impact factor: 3.588

6.  ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.

Authors:  A A Keshgegian
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

7.  Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index.

Authors:  Mu-Tai Liu; Wen-Tao Huang; Ai-Yih Wang; Chia-Chun Huang; Chao-Yuan Huang; Tung-Hao Chang; Chu-Pin Pi; Hao-Han Yang
Journal:  Support Care Cancer       Date:  2009-11-11       Impact factor: 3.603

8.  The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients.

Authors:  Dong L Barraclough; Angela Platt-Higgins; Suzete de Silva Rudland; Roger Barraclough; John Winstanley; Christopher R West; Philip S Rudland
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

9.  The epidermal growth factor receptor family in breast cancer.

Authors:  Angelos K Koutras; T R Jeffry Evans
Journal:  Onco Targets Ther       Date:  2008-09-01       Impact factor: 4.147

10.  The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer.

Authors:  I Brotherick; B K Shenton; W K Cowan; B Angus; C H Horne; M J Higgs; T W Lennard
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.